Polyglutamine (polyQ) diseases are a group of hereditary neurodegenerative disorders caused by expansion of unstable polyQ repeats in their associated disease proteins. To date, the pathogenesis of each disease remains poorly understood, and there are no effective treatments. Growing evidence has indicated that, in addition to neurodegeneration, polyQ-expanded proteins can cause a wide array of abnormalities in peripheral tissues. Indeed, polyQ-expanded proteins are ubiquitously expressed throughout the body and can affect the function of both the central nervous system (CNS) and peripheral tissues. The peripheral effects of polyQ disease proteins include muscle wasting and reduced muscle strength in patients or animal models of spinal and bulbar muscular atrophy (SBMA), Huntington’s disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), and spinocerebellar ataxia type 17 (SCA17). Since skeletal muscle pathology can reflect disease progression and is more accessible for treatment than neurodegeneration in the CNS, understanding how polyQ disease proteins affect skeletal muscle will help elucidate disease mechanisms and the development of new therapeutics. In this review, we focus on important findings in terms of skeletal muscle pathology in polyQ diseases and also discuss the potential mechanisms underlying the major peripheral effects of polyQ disease proteins, as well as their therapeutic implications.
AskanasVEngelWK. 2008. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains. Acta Neuropathol116:583–95.
2.
BatesGPDorseyRGusellaJFHaydenMRKayCLeavittBR and others. 2015. Huntington disease. Nat Rev Dis Primers1:15005.
3.
BorgiaDMalenaASpinazziMDesbatsMASalviatiLRussellAP and others. 2017. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. Hum Mol Genet26:1087–103.
4.
BusseMEHughesGWilesCMRosserAE. 2008. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington’s disease. J Neurol255:1534–40.
5.
CarrollJBBatesGPSteffanJSaftCTabriziSJ. 2015. Treating the whole body in Huntington’s disease. Lancet Neurol14:1135–42.
6.
CiammolaASassoneJSciaccoMMencacciNERipoloneMBizziC and others. 2011. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington’s disease. Mov Disord26:130–7.
7.
CortesCJLingSCGuoLTHungGTsunemiTLyL and others. 2014. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron82:295–307.
8.
CoxHCostin-KellyNMRamaniP.2000. An established case of dentatorubral pallidoluysian atrophy (DRPLA) with unusual features on muscle biopsy. Eur J Padiatr Neurol4:119–23.
9.
DisatnikMHJoshiAUSawNLShamlooMLeavittBRQiX and others. 2016. Potential biomarkers to follow the progression and treatment response of Huntington’s disease. J Exp Med213:2655–69.
10.
FunakoshiHBelluardoNArenasEYamamotoYCasabonaAPerssonH and others. 1995. Muscle-derived neurotrophin-4 as an activity-dependent trophic signal for adult motor neurons. Science. 268(5216):1495–9.
11.
FujimotoMTakakiEHayashiTKitauraYTanakaYInouyeS and others. 2005. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem280:34908–16.
12.
GiorgettiEYuZChuaJPShimamuraRZhaoLZhuF and others. 2016. Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep17:125–36.
13.
GizatullinaZZLindenbergKSHarjesPChenYKosinskiCMLandwehrmeyerBG and others. 2006. Low stability of Huntington muscle mitochondria against Ca2+ in R6/2 mice. Ann Neurol59:407–11.
14.
HuangSYangSGuoJYanSGaertigMALiS and others. 2015. Large polyglutamine repeats cause muscle degeneration in SCA17 mice. Cell Rep13(1):196–208.
15.
KoroshetzWJJenkinsBGRosenBRBealMF. 1997. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol41:160–5.
16.
KosinskiCMSchlangenCGellerichFNGizatullinaZDeschauerMSchieferJ and others. 2007. Myopathy as a first symptom of Huntington’s disease in a marathon runner. Mov Disord22:1637–40.
17.
LiSHLiXJ. 2004. Huntingtin protein interactions and the pathogenesis of Huntington’s disease. Trends Genet20:146–54.
18.
LiebermanAPShakkottaiVGAlbinRL. 2018. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol. Aug 8 Epub ahead of print. doi:10.1146/annurev-pathmechdis-012418-012857
19.
LiebermanAPYuZMurraySPeraltaRLowAGuoS and others. 2014. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep7:774–84.
20.
LodiRSchapiraAHMannersDStylesPWoodNWTaylorDJ and others. 2000. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol48:72–6.
21.
LoefflerJPPicchiarelliGDupuisLGonzalezDeAguilarJL. 2016. The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol26:227–36.
22.
MalenaAPennutoMTezzeCQuerinGD’AscenzoCSilaniV and others. 2013. Androgen-dependent impairment of myogenesis in spinal and bulbar muscular atrophy. Acta Neuropathol126:109–21.
23.
McCampbellATaylorJPTayeAARobitschekJLiMWalcottJ and others. 2000. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet9:2197–202.
24.
MelkaniGCTrujilloASRamosRBodmerRBernsteinSIOcorrK.2013. Huntington’s disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet9:e1004024.
25.
MoffittHMcPhailGDWoodmanBHobbsCBatesGP. 2009. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington’s disease. PLoS One4:e8025.
26.
MonksDAJohansenJAMoKRaoPEaglesonBYuZ and others. 2007. Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A104:18259–64.
27.
OrrHTZoghbiHY. 2007. Trinucleotide repeat disorders. Annu Rev Neurosci30:575–621.
QuerinGBertolinCDaRe EVolpeMZaraGPegoraroE and others. 2016. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry87:810–6.
30.
PalazzoloIStackCKongLMusaroAAdachiHKatsunoM and others. 2009. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron63:316–28.
31.
PaulsonHLShakkottaiVGClarkHBOrrHT. 2017. Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci18:613–26.
32.
RanganathanSHarmisonGGMeyertholenKPennutoMBurnettBGFischbeckKH. 2009. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum Mol Genet18:27–42.
33.
ReddyPH. 2014. Increased mitochondrial fission and neuronal dysfunction in Huntington’s disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today19:951–5.
34.
RibchesterRRThomsonDWoodNIHinksTGillingwaterTHWishartTM and others. 2004. Progressive abnormalities in skeletal muscle and neuro-muscular junctions of transgenic mice expressing the Huntington’s disease mutation. Eur J Neurosci20:3092–114.
35.
RocchiAMiliotoCParodiSArmirottiABorgiaDPellegriniM and others. 2016. Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol132:127–44.
36.
RossCAAylwardEHWildEJLangbehnDRLongJDWarnerJH and others. 2014. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol10(4):204–16.
37.
RusminiPPolancoMJCristofaniRCicardiMEMeroniMGalbiatiM and others. 2015. Aberrant autophagic response in the muscle of a knock in mouse model of spinal and bulbar muscular atrophy. Sci Rep5:15174.
38.
SaftCZangeJAndrichJMüllerKLindenbergKLandwehrmeyerB and others. 2005. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord20:674–9.
39.
SassoneJColciagoCCislaghiGSilaniVCiammolaA.2009. Huntington’s disease: the current state of research with peripheral tissues. Exp Neurol219:385–97.
40.
SathasivamKHobbsCTurmaineMMangiariniLMahalABertauxF and others. 1999. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet8:813–22.
41.
SaudouFHumbertS.2016. The biology of Huntingtin. Neuron89(5):910–26.
42.
ShePZhangZMarchioniniDDiazWCJettonTJKimballSR and others 2011. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington’s disease. Am J Physiol Endocrinol Metab301:E49–61.
43.
SorarùGD’AscenzoCPoloAPalmieriABaggioLVerganiL and others. 2008. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci264:100–5.
44.
StrandADAragakiAKShawDBirdTHoltonJTurnerC and others. 2005. Gene expression in Huntington’s disease skeletal muscle: a potential biomarker. Hum Mol Genet14:1863–76.
45.
StrandADBaquetZCAragakiAKHolmansPYangLClerenC and others. 2007. Expression profiling of Huntington’s disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci27:11758–68.
46.
TurnerCCooperJMSchapiraAH. 2007. Clinical correlates of mitochondrial function in Huntington’s disease muscle. Mov Disord22:1715–21.
47.
ValadãoPAde AragãoBCAndradeJNMagalhães-GomesMPFoureauxGJoviano SantosJV and others. 2017. Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington’s disease. Eur J Neurosci45:785–96.
48.
van der BurgJMBjörkqvistMBrundinP.2009. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol8:765–74.
49.
van Roon-MomWMReidSJFaullRLSnellRG. 2005. TATA-binding protein in neurodegenerative disease. Neuroscience133:863–72.
50.
YangSChangRYangHZhaoTHongYKongHE and others. 2017. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest127:2719–24.
51.
YuZDadgarNAlbertelliMGruisKJordanCRobinsDM and others. 2006. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J Clin Invest116:2663–72.
52.
ZielonkaDPiotrowskaIMarcinkowskiJT. 2014. Skeletal muscle pathology in Huntington’s disease. Front Physiol5:380.
